PP2A counterbalances Phosphorylation of pRB and mitotic proteins by multiple CDKs: Potential implications for PP2A disruption in cancer

Genes and Cancer

Volumn 3, Issue 11-12, 2012, Pages 739-748

  Kurimchak, Alison ^a   Graña, Xavier ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

B55 ; Cyclins; p107; p130; PP2A inhibitors; PPP2R2A; Tumor suppressor

Indexed keywords

CELL PROTEIN; CYCLIN DEPENDENT KINASE; MESSENGER RNA; PHOSPHOPROTEIN PHOSPHATASE 2; PHOSPHOPROTEIN PHOSPHATASE 2A; RETINOBLASTOMA PROTEIN; TUMOR SUPPRESSOR PROTEIN;

ADENOVIRUS; CARBOXY TERMINAL SEQUENCE; CELL DAMAGE; CELL IMMORTALIZATION; COMPLEX FORMATION; ENZYME ACTIVITY; ENZYME INHIBITION; GENE DELETION; HAPLOINSUFFICIENCY; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; OPEN READING FRAME; PPP2R1A GENE; PPP2R1B GENE; PPP2R2A GENE; PPP2R2B GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; SIMIAN VIRUS 40; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR GENE; TUMOR PROMOTION;

EID: 84880497002     PISSN: 19476019     EISSN: 19476027     Source Type: Journal    
DOI: 10.1177/1947601912473479     Document Type: Review

References (90)

1. Shi Y. Serine/threonine phosphatases: mechanism through structure. Cell 2009;139:468-484.
2. Virshup DM, Shenolikar, S. From promiscuity to precision: protein phosphatases get a makeover. Mol Cell. 2009;33:537-545.
3. Kurimchak A, Graña X. PP2A holoenzymes negatively and positively regulate cell cycle progression by dephosphorylating pocket proteins and multiple CDK substrates. Gene. 2012;499:1-7.
4. Eichhorn PJ, Creyghton MP, Bernards R. Protein phosphatase 2A regulatory subunits and cancer. Biochim Biophys Acta. 2009;1795:1-15.
5. Kolupaeva V, Janssens V. PP1 and PP2A phosphatases- cooperating partners in modulating retinoblastoma protein activation. FEBS J. Epub 2012 Feb 2.
6. Cohen P, Holmes CF, Tsukitani Y. Okadaic acid: a new probe for the study of cellular regulation. Trends Biochem Sci. 1990;15:98-102.
7. Bialojan C, Takai A. Inhibitory effect of a marine-sponge toxin, okadaic acid, on protein phosphatases:xpecificity and kinetics. Biochem J. 1988;256:283-290.
8. Fujiki H, Suganuma M, Suguri H, et al. Induction of ornithine decarboxylase activity in mouse skin by a possible tumor promoter, okadaic acid. Proc Jpn Acad Ser B Phys Biol Sci. 1987;63:51-53.
9. Suganuma M, Fujiki H, Suguri H, et al. Okadaic acid: an additional non-phorbol-12-tetradecanoate- 13-acetate-type tumor promoter. Proc Natl Acad Sci U S A. 1988;85:1768-1771.
10. Suganuma M, Fujiki H, Furuya-Suguri H, et al. Calyculin A, an inhibitor of protein phosphatases, a potent tumor promoter on CD-1 mouse skin. Cancer Res. 1990;50:3521-3525.
11. Ishihara H, Martin B. L, Brautigan DL, et al. Calyculin A and okadaic acid: inhibitors of protein phosphatase activity. Biochem Biophys Res Commun. 1989;159:871-877.
12. Suganuma M, Fujiki H, Okabe S, et al. Structurally different members of the okadaic acid class selectively inhibit protein serine/threonine but not tyrosine phosphatase activity. Toxicon. 1992;30:873-878.
13. Ali SH, DeCaprio JA. Cellular transformation by SV40 large T antigen: interaction with host proteins. Semin Cancer Biol. 2001;11:15-23.
14. Pallas DC, Cherington V, Morgan W, et al. Cellular proteins that associate with the middle and small T antigens of polyomavirus. J Virol. 1988;62:3934-3940.
15. Walter G, Carbone-Wiley A, Joshi B, Rundell K. Homologous cellular proteins associated with simian virus 40 small T antigen and polyomavirus medium T antigen. J Virol. 1988;62:4760-4762.
16. Yang YC, Hearing P, Rundell K. Cellular proteins associated with simian virus 40 early gene products in newly infected cells. J Virol. 1979;32:147-154.
17. Grussenmeyer T, Scheidtmann KH, Hutchinson MA, Eckhart W, Walter G. Complexes of polyoma virus medium T antigen and cellular proteins. Proc Natl Acad Sci U S A. 1985;82:7952-7954.
18. Pallas DC, Shahrik LK, Martin BL, et al. Polyoma small and middle T antigens and SV40 small t antigen form stable complexes with protein phosphatase 2A. Cell. 1990;60:167-176.
19. Walter G, Ruediger R, Slaughter C, Mumby M. Association of protein phosphatase 2A with polyoma virus medium tumor antigen. Proc Natl Acad Sci U S A. 1990;87:2521-2525.
20. Arroyo JD, Hahn WC. Involvement of PP2A in viral and cellular transformation. Oncogene. 2005;24:7746-7755.
21. Sontag E, Fedorov S, Kamibayashi C, Robbins D, Cobb M, Mumby M. The interaction of SV40 small tumor antigen with protein phosphatase 2A stimulates the map kinase pathway and induces cell proliferation. Cell. 1993;75:887-897.
22. Chen W, Possemato R, Campbell KT, Plattner CA, Pallas DC, Hahn WC. Identification of specific PP2A complexes involved in human cell transformation. Cancer Cell. 2004;5:127-136.
23. Jayadeva G, Kurimchak A, Garriga J, et al. B55alpha PP2A holoenzymes modulate the phosphorylation status of the retinoblastoma-related protein p107 and its activation. J Biol Chem. 2010;285:29863-29873.
24. Yang SI, Lickteig RL, Estes R, Rundell K, Walter G, Mumby MC. Control of protein phosphatase 2A by simian virus 40 small-t antigen. Mol Cell Biol. 1991;11:1988-1995.
25. Cho US, Morrone S, Sablina AA, Arroyo JD, Hahn WC, Xu W. Structural basis of PP2A inhibition by small t antigen. PLoS Biol. 2007;5:e202.
26. Chen Y, Xu Y, Bao Q, et al. Structural and biochemical insights into the regulation of protein phosphatase 2A by small t antigen of SV40. Nat Struct Mol Biol. 2007;14:527-534.
27. Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, Brooks MW, Weinberg RA. Creation of human tumour cells with defined genetic elements. Nature. 1999;400:464-468.
28. Chen W, Hahn WC. SV40 early region oncoproteins and human cell transformation. Histol Histopathol. 2003;18:541-550.
29. Hahn WC, Dessain SK, Brooks MW, et al. Enumeration of the simian virus 40 early region elements necessary for human cell transformation. Mol Cell Biol. 2002;22:2111-2123.
30. Sablina AA, Hector M, Colpaert N, Hahn WC. Identification of PP2A complexes and pathways involved in cell transformation. Cancer Res. 2010;70:10474-10484.
31. Kleinberger T, Shenk T. Adenovirus E4orf4 protein binds to protein phosphatase 2A, and the complex down regulates E1A-enhanced junB transcription. J Virol. 1993;67:7556-7560.
32. Shtrichman R, Sharf R, Barr H, Dobner T, Kleinberger T. Induction of apoptosis by adenovirus E4orf4 protein is specific to transformed cells and requires an interaction with protein phosphatase 2A. Proc Natl Acad Sci U S A. 1999;96:10080-10085.
33. Shtrichman R, Sharf R, Kleinberger T. Adenovirus E4orf4 protein interacts with both Balpha and B′ subunits of protein phosphatase 2A, but E4orf4-induced apoptosis is mediated only by the interaction with Balpha. Oncogene. 2000;19:3757-3765.
34. Van Hoof C, Goris J. Phosphatases in apoptosis: to be or not to be, PP2A is in the heart of the question. Biochim Biophys Acta. 2003;1640:97-104.
35. Marcellus RC, Chan H, Paquette D, Thirlwell S, Boivin D, Branton PE. Induction of p53-independent apoptosis by the adenovirus E4orf4 protein requires binding to the Balpha subunit of protein phosphatase 2A. J Virol. 2000;74:7869-7877.
36. Ben-Israel H, Sharf R, Rechavi G, Kleinberger T. Adenovirus E4orf4 protein downregulates MYC expression through interaction with the PP2AB55 subunit. J Virol. 2008;82:9381-9388.
37. Li S, Brignole C, Marcellus R, et al. The adenovirus E4orf4 protein induces G2/M arrest and cell death by blocking protein phosphatase 2A activity regulated by the B55 subunit. J Virol. 2009;83:8340-8352.
38. Branton PE, Roopchand DE. The role of adenovirus E4orf4 protein in viral replication and cell killing. Oncogene. 2001;20:7855-7865.
39. Soo Hoo L, Zhang JY, Chan EK. Cloning and characterization of a novel 90 kDa "companion" auto-antigen of p62 overexpressed in cancer. Oncogene. 2002;21:5006-5015.
40. Yeh E, Cunningham M, Arnold H, et al. A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. Nat Cell Biol. 2004;6:308-318.
41. Arnold HK, Sears RC. Protein phosphatase 2A regulatory subunit B56alpha associates with c-myc and negatively regulates c-myc accumulation. Mol Cell Biol. 2006;26:2832-2844.
42. Junttila MR, Puustinen P, Niemela M, et al. CIP2A inhibits PP2A in human malignancies. Cell. 2007;130:51-62.
43. Khanna A, Bockelman C, Hemmes A, et al. MYC-dependent regulation and prognostic role of CIP2A in gastric cancer. J Natl Cancer Inst. 2009;101:793-805.
44. Westermarck J, Hahn WC. Multiple pathways regulated by the tumor suppressor PP2A in transformation. Trends Mol Med. 2008;14:152-160.
45. Come C, Laine A, Chanrion M, et al. CIP2A is associated with human breast cancer aggressivity. Clin Cancer Res. 2009;15:5092-5100.
46. Li M, Guo H, Damuni Z. Purification and characterization of two potent heat-stable protein inhibitors of protein phosphatase 2A from bovine kidney. Biochemistry. 1995;34:1988-1996.
47. Li M, Makkinje A, Damuni Z. The myeloid leukemia-associated protein SET is a potent inhibitor of protein phosphatase 2A. J Biol Chem. 1996;271:11059-11062.
48. von Lindern M, van Baal S, Wiegant J, Raap A, Hagemeijer A, Grosveld G. Can, a putative oncogene associated with myeloid leukemogenesis, may be activated by fusion of its 3′ half to different genes: characterization of the set gene. Mol Cell Biol. 1992;12:3346-3355.
49. Neviani P, Santhanam R, Trotta R, et al. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell. 2005;8:355-368.
50. Wang SS., Esplin ED, & Li JL, et al. Alterations of the PPP2R1B gene in human lung and colon cancer. Science. 1998;282:284-287.
51. Calin GA, di Iasio MG, Caprini E, et al. Low frequency of alterations of the alpha (PPP2R1A) and beta (PPP2R1B) isoforms of the subunit A of the serine-threonine phosphatase 2A in human neoplasms. Oncogene. 2000;19:1191-1195.
52. Ruediger R, Hentz M, Fait J, Mumby M, Walter G. Molecular model of the A subunit of protein phosphatase 2A: interaction with other subunits and tumor antigens. J Virol. 1994;68:123-129.
53. Ruediger R, Pham HT, Walter G. Disruption of protein phosphatase 2A subunit interaction in human cancers with mutations in the A alpha subunit gene. Oncogene. 2001;20:10-15.
54. Ruediger R, Pham HT, Walter G. Alterations in protein phosphatase 2A subunit interaction in human carcinomas of the lung and colon with mutations in the A beta subunit gene. Oncogene. 2001;20:1892-1899.
55. Chen W, Arroyo JD, Timmons JC, Possemato R, Hahn WC. Cancer-associated PP2A Aalpha subunits induce functional haploinsufficiency and tumorigenicity. Cancer Res. 2005;65:8183-8192.
56. Ruediger R, Ruiz J, Walter G. Human cancerassociated mutations in the Aalpha subunit of protein phosphatase 2A increase lung cancer incidence in Aalpha knock-in and knockout mice. Mol Cell Biol. 2011;31:3832-3844.
57. Walter G, Ruediger R. Mouse model for probing tumor suppressor activity of protein phosphatase 2A in diverse signaling pathways. Cell Cycle. 2012;11:451-459.
58. Cheng Y, Liu W, Kim ST, et al. Evaluation of PPP2R2A as a prostate cancer susceptibility gene: a comprehensive germline and somatic study. Cancer Genet. 2011;204:375-381.
59. Mao X, Boyd LK, Yanez-Munoz RJ, et al. Chromosome rearrangement associated inactivation of tumour suppressor genes in prostate cancer. Am J Cancer Res. 2011;1:604-617.
60. Taylor BS, Schultz N, Hieronymus H, et al. L. Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010;18:11-22.
61. Liu W, Xie CC, Zhu Y, et al. Homozygous deletions and recurrent amplifications implicate new genes involved in prostate cancer. Neoplasia. 2008;10:897-907.
62. He WW, Sciavolino PJ, Wing J, et al. A novel human prostate-specific, androgen-regulated homeobox gene (NKX3.1) that maps to 8p21, a region frequently deleted in prostate cancer. Genomics. 1997;43:69-77.
63. Bhatia-Gaur R, Donjacour AA, Sciavolino PJ, et al. Roles for Nkx3.1 in prostate development and cancer. Genes Dev. 1999;13:966-977.
64. Curtis C, Shah SP, Chin SF, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012;486:346-352.
65. Network TCGAR. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474:609-615.
66. Tan J, Lee PL, Li Z, et al. B55beta-associated PP2A complex controls PDK1-directed myc signaling and modulates rapamycin sensitivity in colorectal cancer. Cancer Cell. 2010;18:459-471.
67. Muggerud AA, Ronneberg JA, Warnberg F, et al. Frequent aberrant DNA methylation of ABCB1, FOXC1, PPP2R2B and PTEN in ductal carcinoma in situ and early invasive breast cancer. Breast Cancer Res. 2010;12:R3.
68. Dick FA. Structure-function analysis of the retinoblastoma tumor suppressor protein-is the whole a sum of its parts? Cell Div. 2007;2:26.
69. Sotillo E, Graña X. Escape from cellular quiescence. In: Cell cycle deregulation in cancer, contemporary cancer research New York, NY: Springer Publishing; 2010. p. 3-22.
70. Rowland BD, Bernards R. Re-evaluating cellcycle regulation by E2Fs. Cell. 2006;127:871-874.
71. Durfee T, Becherer K, Chen PL, et al. The retinoblastoma protein associates with the protein phosphatase type 1 catalytic subunit. Genes Dev. 1993;7:555-569.
72. Nelson DA, Krucher NA, Ludlow JW. High molecular weight protein phosphatase type 1 dephosphorylates the retinoblastoma protein. J Biol Chem. 1997;272:4528-4535.
73. Nelson DA, Ludlow JW. Characterization of the mitotic phase pRb-directed protein phosphatase activity. Oncogene. 1997;14:2407-2415.
74. Garriga J, Jayaraman AL, Limon A, et al. A dynamic equilibrium between CDKs and PP2A modulates phosphorylation of pRB, p107 and p130. Cell Cycle. 2004;3:1320-30.
75. An B, Dineley K, Zhang L, Termin T, Meijer L, Dou Q. Involvement of RB kinases and phosphatases in life and death decisions. Oncol Rep. 1997;4:1129-1134.
76. Magenta A, Fasanaro P, Romani S, et al. Protein phosphatase 2A subunit PR70 interacts with pRb and mediates its dephosphorylation. Mol Cell Biol. 2008;28:873-882.
77. Xu Y, Chen Y, Zhang P, Jeffrey PD, Shi Y. Structure of a protein phosphatase 2A holoenzyme: insights into B55-mediated Tau dephosphorylation. Mol Cell. 2008;31:873-885.
78. Wurzenberger C, Gerlich DW. Phosphatases: providing safe passage through mitotic exit. Nat Rev Mol Cell Biol. 2011;12:469-482.
79. Schmitz MH, Held M, Janssens V, et al. Livecell imaging RNAi screen identifies PP2AB55alpha and importin-beta1 as key mitotic exit regulators in human cells. Nat Cell Biol. 2009;12:886-893.
80. Mayer-Jaekel RE, Ohkura H, Ferrigno P, et al. Drosophila mutants in the 55 kDa regulatory subunit of protein phosphatase 2A show strongly reduced ability to dephosphorylate substrates of p34cdc2. J Cell Sci. 1994;107(Pt 9):2609-2616.
81. Castilho PV, Williams BC, Mochida S, Zhao Y, Goldberg ML. The M phase kinase Greatwall (Gwl) promotes inactivation of PP2A/B55delta, a phosphatase directed against CDK phosphosites. Mol Biol Cell. 2009;20:4777-4789.
82. Vigneron S, Brioudes E, Burgess A, Labbe JC, Lorca T, Castro A. Greatwall maintains mitosis through regulation of PP2A. EMBO J. 2009;28:2786-2793.
83. Mochida S, Ikeo S, Gannon J, Hunt T. Regulated activity of PP2A-B55 delta is crucial for controlling entry into and exit from mitosis in Xenopus egg extracts. EMBO J. 2009;28:2777-2785.
84. Gharbi-Ayachi A, Labbe JC, Burgess A, et al. The substrate of Greatwall kinase, Arpp19, controls mitosis by inhibiting protein phosphatase 2A. Science. 2010;330:1673-1677.
85. Mochida S, Maslen SL, Skehel M, Hunt T. Greatwall phosphorylates an inhibitor of protein phosphatase 2A that is essential for mitosis. Science. 2010;330:1670-1673.
86. Manchado E, Guillamot M, de Carcer G, et al. Targeting mitotic exit leads to tumor regression in vivo: modulation by Cdk1, Mastl, and the PP2A/B55alpha,delta phosphatase. Cancer Cell. 2010;18:641-654.
87. Wallington-Beddoe CT, Don AS, Hewson J, et al. Disparate in vivo efficacy of FTY720 in xenograft models of Philadelphia positive and negative B-lineage acute lymphoblastic leukemia. PLoS One. 2012;7:e36429.
88. Liu Q, Zhao X, Frissora F, et al. FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/ lymphoma. Blood. 2008;111:275-284.
89. Neviani P, Santhanam R, Oaks JJ, et al. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. J Clin Invest. 2007;117:2408-2421.
90. Wang JD, Takahara S, Nonomura N, et al. Early induction of apoptosis in androgen-independent prostate cancer cell line by FTY720 requires caspase- 3 activation. Prostate. 1999;40:50-55.